Liposome-mediated gene therapy in the kidney

Human Cell
Keiichi ItoDiane Felsen

Abstract

Gene therapy directed to the kidney has been attempted to improve renal disorders such as inherited kidney diseases and common renal diseases that cause interstitial fibrosis, tubular atrophy, and glomerulosclerosis. Viral and non-viral vectors have been tried and been modulated to obtain sufficient transgene expression. However, gene delivery to the kidney is usually difficult because of characteristics of renal cell biology. Among non-viral vectors, the liposome system is a promising procedure for kidney-targeted gene therapy. Using cationic liposome, tubular cells were effectively transduced by retrograde injection of liposome/cDNA complex. Although transgene expression was reportedly modest using cationic liposomes, this method improved renal disease models such as carbonic anhydrase II deficiency and unilateral ureteral obstruction. In contrast, HVJ-liposome system is an effective transfection method to glomerular cells using intra-renal arterial infusion and improved glomerular disease models such as glomerulonephritis and glomerulosclerosis. In addition, intra-renal pelvic injection of DNA by HVJ-liposome system showed transgene expression in interstitial fibroblasts. In kidney-targeted gene therapy, liposome-mediated ge...Continue Reading

References

Jul 15, 1992·Biochemical and Biophysical Research Communications·N TomitaT Ogihara
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·P L FelgnerM Danielsen
Jul 1, 1994·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·S Bachmann, P Mundel
Jun 1, 1995·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Y KanedaN Tomita
Apr 1, 1994·Kidney International·P MoullierN Ferry
Jan 1, 1993·Kidney International·K TryggvasonT B Shows
Jul 1, 1996·Kidney International·L D TruongW N Suki
Oct 1, 1996·Journal of the American Society of Nephrology : JASN·J J MorrisseyS Klahr
Mar 19, 1997·Journal of the National Cancer Institute·K XieI J Fidler
May 1, 1997·Gene Therapy·L W LaiY H Lien
Feb 14, 1998·Kidney International·E Imai, Y Isaka
Apr 29, 1998·The Journal of Clinical Investigation·L W LaiY H Lien
Jun 17, 1998·The Journal of Clinical Investigation·Y MaeshimaH Makino
Jun 10, 1998·Biochemical and Biophysical Research Communications·F J ThorntonA Barbul
Sep 7, 1999·Journal of the American Society of Nephrology : JASN·M S LipkowitzM E Klotman
Feb 26, 2000·Cardiovascular Research·M KibbeE Tzeng
Jun 23, 2000·Journal of the American Society of Nephrology : JASN·Naruya TomitaToshio Ogihara
Nov 25, 2000·Laboratory Investigation; a Journal of Technical Methods and Pathology·D HochbergD Felsen
Mar 7, 2001·Kidney International·N J HegartyJ M Fitzpatrick
Sep 18, 2002·Kidney International·Xiaojie GaoTakakuni Tanizawa
Dec 11, 2002·American Journal of Physiology. Renal Physiology·Kazuaki MoridairaSaulo Klahr
Apr 16, 2003·Kidney International. Supplement·Bernhard BrüneAndreas von Knethen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Expert Opinion on Investigational Drugs
Enyu Imai, Yoshitaka Isaka
Nihon rinsho. Japanese journal of clinical medicine
Yasufumi Kaneda
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Enyu Imai
© 2021 Meta ULC. All rights reserved